A detailed history of Northern Trust Corp transactions in Aurinia Pharmaceuticals Inc. stock. As of the latest transaction made, Northern Trust Corp holds 995,689 shares of AUPH stock, worth $8.94 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
995,689
Previous 979,984 1.6%
Holding current value
$8.94 Million
Previous $5.6 Million 30.44%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$5.32 - $7.33 $83,550 - $115,117
15,705 Added 1.6%
995,689 $7.3 Million
Q2 2024

Aug 14, 2024

SELL
$4.81 - $5.78 $205,906 - $247,430
-42,808 Reduced 4.19%
979,984 $5.6 Million
Q1 2024

May 14, 2024

SELL
$4.93 - $9.31 $218,808 - $413,205
-44,383 Reduced 4.16%
1,022,792 $5.12 Million
Q4 2023

Feb 13, 2024

BUY
$7.13 - $9.49 $155,391 - $206,825
21,794 Added 2.08%
1,067,175 $9.59 Million
Q3 2023

Nov 13, 2023

BUY
$7.77 - $12.27 $274,995 - $434,259
35,392 Added 3.5%
1,045,381 $8.12 Million
Q2 2023

Aug 11, 2023

BUY
$8.96 - $11.69 $217,450 - $283,704
24,269 Added 2.46%
1,009,989 $9.78 Million
Q1 2023

May 15, 2023

SELL
$5.94 - $11.27 $245,898 - $466,544
-41,397 Reduced 4.03%
985,720 $10.8 Million
Q4 2022

Feb 13, 2023

BUY
$4.11 - $8.14 $91,443 - $181,106
22,249 Added 2.21%
1,027,117 $4.44 Million
Q3 2022

Nov 14, 2022

SELL
$6.66 - $12.39 $96,230 - $179,023
-14,449 Reduced 1.42%
1,004,868 $7.56 Million
Q2 2022

Aug 12, 2022

BUY
$8.95 - $12.8 $8.21 Million - $11.7 Million
917,113 Added 897.34%
1,019,317 $10.2 Million
Q1 2022

May 13, 2022

BUY
$10.05 - $22.48 $7,316 - $16,365
728 Added 0.72%
102,204 $1.27 Million
Q4 2021

Feb 08, 2022

BUY
$17.78 - $33.08 $81,948 - $152,465
4,609 Added 4.76%
101,476 $2.32 Million
Q3 2021

Nov 15, 2021

BUY
$10.93 - $23.55 $1.06 Million - $2.28 Million
96,867 New
96,867 $2.14 Million

Others Institutions Holding AUPH

About Aurinia Pharmaceuticals Inc.


  • Ticker AUPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,892,000
  • Market Cap $1.27B
  • Description
  • Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...
More about AUPH
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.